Barclays’s Tonix Pharmaceuticals TNXP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$93.7K Buy
7,346
+797
+12% +$10.3K ﹤0.01% 4063
2026
Q1
$90K Sell
6,549
-15,682
-71% -$241K ﹤0.01% 4073
2025
Q4
$347K Buy
22,231
+9,765
+78% +$180K ﹤0.01% 4056
2025
Q3
$301K Sell
12,466
-833
-6% -$30.9K ﹤0.01% 4098
2025
Q2
$478K Buy
+13,299
New +$348K ﹤0.01% 3781
2018
Q2
– Hold
0
– – – 7281
2018
Q1
– Hold
0
– – – 7330
2017
Q2
– Hold
0
– – – 6928
2017
Q1
– Hold
0
– – – 6975
2013
Q4
– Hold
0
– -$2K – 7680
2013
Q3
– Hold
0
– – – 7207

Other funds holding TNXP

Barclays's TNXP Position: Q2 2026 in Review

Barclays increased its Tonix Pharmaceuticals (TNXP) stake by 12% in Q2 2026, buying an estimated $10.3K and bringing the position to 7,346 shares worth $93.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4063.

Barclays first reported a position in TNXP in Q2 2025 and has held it in 5 quarters since. The position peaked at $478K in Q2 2025. 102 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.

  • Barclays held 7,346 shares of Tonix Pharmaceuticals worth $93.7K as of Q2 2026.
  • Barclays bought 797 Tonix Pharmaceuticals shares in Q2 2026, an estimated $10.3K.
  • Tonix Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4063 holding.
  • Barclays first reported a position in Tonix Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Barclays's Tonix Pharmaceuticals position peaked at $478K in Q2 2025.
  • 102 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.